Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP Research & Development | October 06, 2026 | October 06, 2026 |
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | June 18, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date October 06, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 153,902 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 3,500 · Balance 157,402 Row 2 · 2026-10-06 · Sale · Disposed 3,500 · Balance 153,902 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2028-02-27 | Direct | 19,886 |
Reported balance
After 2026-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-06 · Exercise / conversion · Disposed 3,500 · Balance 19,886 |
ROCKET PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,862 |
Reported balance
After 2026-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 22,862 · Balance 52,862 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2036-06-18 | Direct | 64,860 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 64,860 · Balance 64,860 F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 6, 2026 20:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-26-000098 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,886 Underlying: Common Stock · 3,500 shares Expires 2028-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 06, 2026 Filed Oct 6, 2026 20:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,500 | $61.38 | $214,830.00 |
DisclosureSEC source: 0001061983-26-000098 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,902 Read SEC document |
| October 06, 2026 Filed Oct 6, 2026 20:25 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0001061983-26-000098 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2026 Filed Sep 22, 2026 22:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-26-000096 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,386 Underlying: Common Stock · 3,500 shares Expires 2028-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2026 Filed Sep 22, 2026 22:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,500 | $68.29 | $239,015.00 |
DisclosureSEC source: 0001061983-26-000096 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,902 Read SEC document |
| September 22, 2026 Filed Sep 22, 2026 22:14 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0001061983-26-000096 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 20:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-26-000092 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,886 Underlying: Common Stock · 3,500 shares Expires 2028-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 20:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,500 | $75.46 | $264,110.00 |
DisclosureSEC source: 0001061983-26-000092 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,902 Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 20:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0001061983-26-000092 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2026 Filed Aug 18, 2026 20:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-26-000088 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,386 Underlying: Common Stock · 3,500 shares Expires 2028-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2026 Filed Aug 18, 2026 20:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,500 | $75.82 | $265,370.00 |
DisclosureSEC source: 0001061983-26-000088 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,902 Read SEC document |
| August 18, 2026 Filed Aug 18, 2026 20:38 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0001061983-26-000088 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2026 Filed Jul 23, 2026 20:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-26-000084 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,886 Underlying: Common Stock · 3,500 shares Expires 2028-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2026 Filed Jul 23, 2026 20:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,500 | $80.59 | $282,065.00 |
DisclosureSEC source: 0001061983-26-000084 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,902 Read SEC document |
| July 21, 2026 Filed Jul 23, 2026 20:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0001061983-26-000084 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2026 Filed Jul 7, 2026 21:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-26-000075 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,386 Underlying: Common Stock · 3,500 shares Expires 2028-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2026 Filed Jul 7, 2026 21:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,500 | $86.62 | $303,170.00 |
DisclosureSEC source: 0001061983-26-000075 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,902 Read SEC document |
| July 07, 2026 Filed Jul 7, 2026 21:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0001061983-26-000075 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2026 Filed Jun 23, 2026 21:41 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-26-000069 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,886 Underlying: Common Stock · 3,500 shares Expires 2028-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2026 Filed Jun 23, 2026 21:41 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,500 | $79.51 | $278,285.00 |
DisclosureSEC source: 0001061983-26-000069 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,902 Read SEC document |
| June 23, 2026 Filed Jun 23, 2026 21:41 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0001061983-26-000069 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2026 Filed Jul 6, 2026 23:59 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 64,860 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001140361-26-027678 · form4.xml · derivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,860 Underlying: Common Stock · 64,860 shares Expires 2036-06-18 F2 · derivative.exercise_date: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jul 6, 2026 23:59 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 22,862 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-027678 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,862 F1 · security: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. F1 · price: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. Read SEC document |
| June 09, 2026 Filed Jun 9, 2026 21:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-26-000067 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,386 Underlying: Common Stock · 3,500 shares Expires 2028-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2026 Filed Jun 9, 2026 21:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,500 | $67.98 | $237,930.00 |
DisclosureSEC source: 0001061983-26-000067 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,902 Read SEC document |
| June 09, 2026 Filed Jun 9, 2026 21:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0001061983-26-000067 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:00 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-26-000053 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,886 Underlying: Common Stock · 3,500 shares Expires 2028-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:00 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,500 | $75.69 | $264,915.00 |
DisclosureSEC source: 0001061983-26-000053 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,902 Read SEC document |
| May 19, 2026 Filed May 20, 2026 20:00 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0001061983-26-000053 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 5, 2026 21:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-26-000051 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,386 Underlying: Common Stock · 3,500 shares Expires 2028-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 5, 2026 21:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,500 | $77.37 | $270,795.00 |
DisclosureSEC source: 0001061983-26-000051 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,902 Read SEC document |
| May 05, 2026 Filed May 5, 2026 21:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0001061983-26-000051 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2026 Filed Apr 21, 2026 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-26-000043 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,886 Underlying: Common Stock · 3,500 shares Expires 2028-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2026 Filed Apr 21, 2026 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,500 | $65.69 | $229,915.00 |
DisclosureSEC source: 0001061983-26-000043 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,902 Read SEC document |
| April 21, 2026 Filed Apr 21, 2026 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0001061983-26-000043 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-26-000034 · form4.xml · derivative · entry 6 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires 2027-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001061983-26-000034 · form4.xml · derivative · entry 5 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,386 Underlying: Common Stock · 3,500 shares Expires 2028-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,000 | $64.75 | $64,750.00 |
DisclosureSEC source: 0001061983-26-000034 · form4.xml · nonDerivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,902 Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 1,000 | $10.60 | $10,600.00 |
DisclosureSEC source: 0001061983-26-000034 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,500 | $65.21 | $228,235.00 |
DisclosureSEC source: 0001061983-26-000034 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,902 Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:18 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,500 | $7.80 | $27,300.00 |
DisclosureSEC source: 0001061983-26-000034 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 21:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,397 | $62.15 | $273,273.55 |
DisclosureSEC source: 0001061983-26-000027 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,902 F2 · kind: Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 21:40 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 7,636 | $62.15 | $474,577.40 |
DisclosureSEC source: 0001061983-26-000027 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,299 F1 · kind: Company compelled sell-to-cover transaction to satisfy tax withholding obligations attributable to RSU vesting. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 39,527 | $0.00 Strike: $60.06 | $0.00 |
DisclosureSEC source: 0001061983-26-000020 · form4.xml · derivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,527 Underlying: Common Stock · 39,527 shares Expires 2036-03-14 F3 · kind: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (Right to Buy) · Derivative | 1,665 | $0.00 Strike: $60.06 | $0.00 |
DisclosureSEC source: 0001061983-26-000020 · form4.xml · derivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,665 Underlying: Common Stock · 1,665 shares Expires 2036-03-14 F2 · kind: Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 20:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 27,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-26-000020 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,935 F1 · kind: Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan. Read SEC document |
| March 09, 2026 Filed Mar 10, 2026 22:03 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,907 | $60.72 | $176,513.04 |
DisclosureSEC source: 0001061983-26-000017 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,629 F1 · kind: Sell to cover transaction to satisfy company tax withholding obligations upon vesting of RSUs. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 1,016 | $62.72 | $63,723.52 |
DisclosureSEC source: 0001061983-25-000055 · form4.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,536 F3 · kind: Withholding of shares for tax withholding on vesting of performance shares. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-25-000055 · form4.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,552 F2 · kind: Performance shares earned upon achieving performance goal. Shares vested immediately. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 21:06 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-25-000055 · form4.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,552 F1 · kind: Performance shares earned upon achieving performance goal. Shares remain subject to 1-year time vesting requirement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.